Suggest a Low-Molecular-Weight Heparin for Cancer-Associated VTE
We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.
The role of DOACs (Eliquis, Xarelto, etc) is expanding. Chest guidelines now favour these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.
But don't recommend jumping to a DOAC first-line to treat or prevent recurrent VTE in patients with cancer. There's limited evidence about the efficacy and safety of DOACs in this case.